Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Replimune Inc.
M.D. Anderson Cancer Center
Incyte Corporation
Apexigen America, Inc.
The Methodist Hospital Research Institute
Assistance Publique Hopitaux De Marseille
Bristol-Myers Squibb
Cambridge University Hospitals NHS Foundation Trust
Asylia Diagnostics BV
BioNTech SE
Bristol-Myers Squibb